Objective: To evaluate the safety, efficacy and pharmacokinetics of alemtuzumab in Japanese patients, we conducted a phase I study in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Methods: Six patients received alemtuzumab by intravenous infusion every other day three times a week for 12 weeks. The dose was gradually escalated on daily basis (3, 10 and then 30 mg) until the patient tolerated. The primary objective was to evaluate the safety of alemtuzumab in Japanese patients and the secondary objectives were to evaluate the overall response rate and the pharmacokinetics. Results: The major treatment-emergent adverse events were anemia, neutropenia (6/6 patients each) and thrombocytopenia (5/6 patients) in hematologic adverse events, and nausea, vomiting, decreased appetite, cytomegalovirus test positive and pyrexia (4/6 patients) in non-hematologic adverse events. As serious adverse events, cytomegalovirus infection, pulmonary tuberculosis and diffuse large B-cell lymphoma were reported in 1/6 patient each. The overall response rate was 33% (95% confidence interval: 4-78) (1/6 patient each achieved complete response and partial response, respectively) and 3/6 patients had stable disease and 1/6 patient had progressive disease. The median time to response was 2.9 months. After last intravenous dosing (Week 12) of alemtuzumab 30 mg every other day three times a week, C max , t max , AUC 0−τ and t 1/2 were higher and CL and V ss were lower than the values observed after the first dose. Conclusions: The efficacy, safety and pharmacokinetics results observed with alemtuzumab in Japanese patients were generally similar to those reported in overseas clinical studies. Alemtuzumab at 30 mg by intravenous infusion every other day three times a week for 12 weeks should be safe and effective similarly in Japanese B-cell chronic lymphocytic leukemia patients. Clinical trial registration no.: NCT00923182.
Introduction
Chronic lymphocytic leukemia (CLL) is characterized by proliferation of CD5 surface antigen-expressing mature B lymphocytes in peripheral blood and bone marrow (1) . CLL is frequently reported in the US and EU, accounting for approximately 30% of all leukemia (2) . In Japan, CLL accounts for~5% of all leukemia and is estimated to occur in~0.5 per 100 000 persons per year (3) .
Chlorambucil, an alkylating agent was first demonstrated to be effective in CLL patients (4) . Subsequently, fludarabine, a purine nucleoside derivative (5) and rituximab, chimeric anti-CD20 monoclonal antibody (mAb), had been introduced and the effects of various combination therapies were investigated (6) (7) (8) (9) . For fit patients, younger than 65 years without comorbidities, chemoimmunotherapy, the combination of fludarabine, cyclophosphamide and rituximab, demonstrated higher response rate and improved overall survival (9) .
Alemtuzumab, humanized anti-CD52 mAb, is also found to be effective for patients with advanced CLL who do not well respond to chlorambucil and fludarabine, and has been used for CLL patients in the US and EU since 2001 (10) (11) (12) .
In Japan, CLL has been mainly treated with fludarabine monotherapy and fludarabine-containing chemotherapy because the indication of rituximab for the treatment of CLL had not been approved. Thus, development of new therapy for CLL was expected because only a limited number of medications are available compared with the US and EU. These backgrounds prompted us to initiate a phase I study to evaluate safety, efficacy and pharmacokinetics (PK) of alemtuzumab in Japanese patients with relapsed or refractory B-cell CLL (B-CLL) in 2010. Currently, ofatumumab is available in Japan as a treatment for CLL in 2013 (13) and alemtuzumab was approved in 2014, too. The treatment with novel therapy is made accessible in Japan.
Patients and methods

Study subjects
Patients who met all of the inclusion criteria and did not meet any of the exclusion criteria were enrolled in the study. Major inclusion criteria were: (i) patients with age ≥20 and <75 years, (ii) signed a written informed consent, (iii) diagnosed with B-CLL according to the 1996 National Cancer Institute Working Group (NCIWG) criteria, (iv) having had received one to three previous treatment regimens for CLL, (v) more than 4 weeks since prior chemotherapy or chemoimmunotherapy for the treatment of CLL, (vi) assumed to have adequate bone marrow, liver and renal functions, (vii) having life expectancy of at least 24 weeks, (viii) requiring treatment for CLL (Rai stage III or IV, or Rai stage 0 to II with at least one of the following: (a) evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia, (b) massive (i.e. >6 cm below the left costal margin) or progressive splenomegaly, (c) progressive lymphocytosis, (d) lymphocyte count ≥100 000/μL, (e) B-symptoms) and (ix) with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
Key exclusion criteria were: patients who are seropositive for human immunodeficiency virus (HIV) antibody, or positive for HBsAg or HCV antibody, having active uncontrolled infection, having history of anaphylaxis following exposure to humanized mAbs, previous treatment with alemtuzumab, pregnant or breast-feeding patients, central nervous system involvement with CLL, having active malignancy, other than CLL, with need for therapy with anticancer drug, tested positive for cytomegalovirus (CMV) (polymerase chain reaction [PCR] assay), complication of autoimmune hemolytic anemia (AIHA) or autoimmune thrombocytopenia, and having small lymphocytic lymphoma.
Ethics and good clinical practice
The study was conducted based on the principles detailed in the Declaration of Helsinki (14) and in accordance with the Good Clinical Practice (GCP) guidelines (15) , applicable laws and regulations. Investigator obtained a written informed content to study participation from each patient prior to commencing study specific procedure. The study protocol had been reviewed and approved by the appropriate Institutional Review Board at each study site prior to study initiation.
Study design
The primary objective was to evaluate the safety of alemtuzumab at a dose of 30 mg in Japanese patients with relapsed or refractory B-CLL. The secondary objectives were to evaluate overall response rate (ORR) and PK of alemtuzumab. This is a phase I study designed to evaluate the safety, efficacy and PK of alemtuzumab in six Japanese patients with relapsed or refractory B-CLL. The study treatment was initiated at 3 mg, which was increased to 10 mg and then 30 mg only when the tolerability had been confirmed. The treatment was continued daily until the patient tolerated a dose of 30 mg as intravenous (IV) infusion over 2 h. Subsequently, the treatment at 30 mg was continued three times a week for up to 12 weeks, including the dose-escalation period. Patients were observed in 24-week follow-up period after the last dose.
Also, antibiotic and antiviral prophylactic medication was strongly recommended for all patients to prevent possible infection associated with alemtuzumab treatment. The patients received oral treatment with controlled-release sulfamethoxazole/trimethoprim formulation (400 mg/80 mg, twice daily three times a week) or famciclovir (250 mg twice daily) until the CD4-positive cell count reaches 200 cells/μL or to the baseline level. In addition, all patients underwent PCR-based CMV test before the study initiation, during the study period once a week and during the follow-up period on Weeks 4 and 8 following the last dosing. Patients who were tested positive for CMV continued to participate in the study to the extent possible while taking an oral antiviral valganciclovir as long as CMV infection did not manifest itself.
Safety, efficacy and PK evaluation
Safety evaluation
Safety was assessed on the basis of physical examinations, vital signs, treatment-emergent adverse events (TEAEs) and laboratory tests. The severity of TEAEs (grade) was graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Event (NCI-CTCAE) v3.0. Further safety assessment was performed by the Data Monitoring Committee (DMC).
Efficacy evaluation
The primary efficacy endpoint was the ORR. The Overall response was assessed by the investigator according to the 1996 NCIWG response criteria for CLL at a frequency of every 4 weeks during the treatment period or every 8 weeks during the follow-up period. The secondary efficacy endpoints were time to response, duration of response and time to progression.
PK evaluation
Serum alemtuzumab concentrations were quantified using a validated solid phase immunoassay at Clinical Specialty Lab Genzyme Corporation (Framingham, USA). During the dose-escalation period (at doses of 3 and 10 mg), blood samples were collected pre-dose and 2.25, 2.5 and 3 h after the start of 2-h infusion. When the first 30 mg dose was administered, blood samples were collected predose and 1 (mid-infusion), 2.25, 2.5, 3, 6, 24, 48 and 72 h after the start of 2-h infusion. Once the maintenance dosing was initiated at 30 mg three times a week, blood samples were collected pre-dose and 2.25 h after the start of the first 2-h infusion of each week. Additional blood samples were collected on Week 12 of 30 mg dosing period at pre-dose and 1 (mid-infusion), 2.25, 2.5, 3, 6, 24, 48, 72 and 96 h after the start of 2-h infusion. These blood samples were analyzed to determine C max (maximum plasma concentration), t max (time to maximum concentration), AUC 0−τ (area under the plasma concentration-time curve from time 0 to last sample point), CL (clearance), V ss (steady-state volume of distribution) and t 1/2 (elimination half-life).
Statistical analysis
Analysis sets Target sample size was six patients in this study. The modified full analysis set (mFAS) consisted of all patients who reached 30 mg alemtuzumab dose within 2 weeks. The mFAS was used as the primary efficacy analysis set. The safety population consisted of all patients who received at least one dose of study medication. The PK population consisted of all patients who received at least one dose of study medication and who had valid data available to calculate PK parameters.
The ORR was presented with its 95% confidence interval (CI) estimated using Clopper-Pearson Exact method. Time to response, duration of response and time to progression were also estimated using the Kaplan-Meier method.
Serum alemtuzumab concentration was summarized by time point and dose level using descriptive statistics. PK parameters were calculated by non-compartmental methods and tabulated by dose level using descriptive statistics.
Results
Patients
Seven patients with B-CLL were enrolled at five study sites from February 2010 to August 2011. One patient was determined to be ineligible during the screening. The remaining six patients received study treatment with alemtuzumab. Table 1 presents the patient characteristics. The median age was 62.5 years and the median body weight was 57.9 kg. The Rai stage at screening was I (1 patient), III (1 patient) or IV (4 patients). Enlarged lymph nodes were observed in five patients, of whom two patients were ≤2 cm in diameter of all nodes. Three patients had at least one node with a diameter between >2 and <5 cm, and hepatomegaly and splenomegaly were observed in one and three patients, respectively. No B-symptoms were observed in any patients at screening. ECOG PS was 0 in 5 patients and 1 in 1 patient. There were three patients diagnosed with CD38-positive because the number of CD38-positive cells was above the cut-off point (30%) in the peripheral blood. The median duration of CLL was 7.5 years. Prior therapies included cyclophosphamide and fludarabine phosphate (five patients each), prednisolone, rituximab and vincristine sulfate (two patients each). The median number of prior regimens of all patients was 2.5, and the median time from immediate prior therapy to the study initiation was 3.5 months.
Safety
Safety analysis was performed on the safety population, which included all six patients who received at least one dose of alemtuzumab. All patients underwent dose escalation to 30 mg within 5 days after treatment initiation. Four of them completed alemtuzumab treatment for 12 weeks and five patients received at least 21 doses of alemtuzumab at 30 mg. One patient discontinued treatment due to progressive disease (PD), another patient discontinued treatment due to AIHA. All six patients experienced at least one grade 3 or 4 TEAE. Serious adverse events (SAEs) were reported in three patients and no deaths were reported in this study. One patient discontinued treatment due to TEAE.
TEAEs are summarized in Table 2 . The major TEAEs were anemia, neutropenia (six patients each) and thrombocytopenia (five patients) in hematologic adverse events (AEs) and decreased appetite, nausea, vomiting and pyrexia (four patients each) in nonhematologic AEs. Positive CMV test was reported in four patients. The major grade 3 or 4 TEAEs were neutropenia (six patients), anemia and thrombocytopenia (three patients each). Of the reported AEs, grade 4 TEAEs were neutropenia (four patients), thrombocytopenia, leukopenia, lymphopenia and diffuse large B-cell lymphoma (one patient each) ( Table 2) .
The major biochemical abnormalities were hyperglycemia (six patients), aspartate aminotransferase (AST) increased, hypoalbuminemia, hypocalcemia (five patients each) and total bilirubin increased (four patients), which were grade 1 or 2 with the exception of grade 3 hyperglycemia and total bilirubin increased (one patient each).
The reported TEAEs related to vital signs were hypotension (two patients) and pyrexia (four patients), all of which were grade 2. Also reported were weight decreased and weight increased (two patients each), all of which were grade 1 or 2. No patients had clinically significant electrocardiogram (ECG) abnormalities.
Three patients experienced infection-related events (pneumonia and pulmonary tuberculosis were reported in one patient, and CMV infection and infections not elsewhere classified (NEC) were reported in one patient each). The CD4-positive cell count was markedly decreased after the first dose of alemtuzumab (six patients, from 206-2918 cells/μL at baseline to 37-335 cells/μL on Week 12 after the first dose), but later recovered to 200 cells/μL or higher during the follow-up period (Fig. 1) . One patient, whose CD4-positive cell count on Week 12 was 37 cells/μL, developed CMV infection of grade 3.
A total of three SAEs were reported in three patients: pulmonary tuberculosis (grade 3), CMV infection (grade 3) and diffuse large B-cell lymphoma (grade 4). It was considered that the causal relationship between the three SAEs and the study treatment cannot be ruled out (i.e. either related or possibly related to the study).
Pulmonary tuberculosis and diffuse large B-cell lymphoma occurred 3 and 8 months after the last dosing, respectively. A patient who experienced grade 3 CMV infection temporally discontinued the study treatment but resumed when the event became grade 1. One patient who developed grade 2 AIHA 1 month after the first dose was discontinued the study treatment. TEAEs that led to dose adjustment, including infusion rate reduction were five events (chills in three patients, pyrexia and hypoxia in one patient each), and TEAEs that led to dose interruption (i.e. temporally stop and re-start) were four events (CMV infection, thrombocytopenia, fatigue and hyperbilirubinaemia in one patient each).
All post-dose samples from six patients were negative for antialemtuzumab antibody. Table 3 presents a summary of the best overall response following alemtuzumab treatment on mFAS. One patient each (17%) achieved complete response (CR) and partial response (PR), three patients (50%) had stable disease (SD) and one patient (17%) had PD. The ORR for the six patients was 33% (95% CI: 4-78). The time to response for the two patients was 1.0 months for the patient TEAEs are reported using MedDRA version 14.0 and graded using CTCAE version 3.0. Biochemical abnormalities are graded using CTCAE version 3.0. CMV, cytomegalovirus; AST, aspartate aminotransferase.
Efficacy
achieving CR, and 4.8 months for the patients achieving PR. Neither of the two responders showed disease progression during the study and therefore the duration of response could not be calculated. Disease progression was observed in three of the six patients (the time was 2.4, 3.7 and 4.6 months). Of the three patients, one was still on the treatment period and two were in the follow-up period. Figure 2 shows serum alemtuzumab concentrations up to 3 h after the first dose of alemtuzumab 3, 10 and 30 mg on PK population. The mean serum alemtuzumab concentration (± standard deviation) at 3 hours after the first dose of alemtuzumab 3, 10 and 30 mg was 14.3 ± 35.11, 159.3 ± 182.79 and 737.2 ± 540.85 ng/mL, respectively. The alemtuzumab concentration after the last dose on Week 12 (16187.5 ± 9145.59 ng/mL) was significantly increased from the concentration after the first dose. Table 4 summarizes PK parameters determined after the first and last dosing (on Week 12) of alemtuzumab 30 mg. In the comparison of PK parameters after the first dosing of alemtuzumab 30 mg with those after the last dosing, C max , t max , AUC 0-τ and t 1/2 were increased and CL and V ss were decreased over the course of 12-week treatment period.
Pharmacokinetics
Discussion
The safety, efficacy and PK profile of administering alemtuzumab at 30 mg (the US/EU approved dose, IV infusion every other day three times a week for 12 weeks) in Japanese patients with relapsed or refractory B-CLL were evaluated and compared with those in overseas clinical studies. In the present study, all six patients experienced at least one TEAE. As major TEAEs, anemia, neutropenia, thrombocytopenia, infections (CMV infection, pneumonia, infections NEC and pulmonary tuberculosis), decreased appetite, nausea, vomiting and pyrexia were reported. Major adverse events reported in overseas clinical studies of alemtuzumab include blood cell count decreased (e.g. anemia, neutropenia and thrombocytopenia), infections (e.g. CMV infection), gastrointestinal disorders (e.g. nausea and vomiting), pyrexia, chills and hypotension (10) (11) (12) . These are generally consistent with TEAEs observed in the present study. The CD4-positive cell count was significantly decreased in five patients but not in the remaining one patient. Immunocompromised patients with acquired immunodeficiency syndrome are reported to be susceptible to opportunistic infections when the CD4-positive cell count is reduced to 200 cells/μL or lower and further become vulnerable to CMV infection when the CD4-positive cell count dips to 50 cells/μL or lower (16) . CLL patients are also reported to be susceptible to infections due to immunodeficiency associated with the primary disease as well as immunosuppression by CLL medications (17) . Similarly, patients with a low CD4-positive cell count in our study experienced pneumonia, infections NEC, pulmonary tuberculosis and CMV infection (one patient each), which were appropriately controlled by antibiotic and antiviral medications to avoid worsening of symptoms. An overseas clinical study reported that the occurrence of TEAEs, including infections, could be reduced by starting alemtuzumab at 3 mg and then up-titrating the dose after confirming the tolerability and that opportunistic infections are greatly suppressed by prophylactic administration of sulfamethoxazole/trimethoprim and famciclovir (11) . Therefore, when alemtuzumab is used in a clinical study or treatment, these infections should be able to control by continuous monitoring of signs of infections along with CD4-positive cell count as well as by appropriate supportive therapies, such as antibiotic and antiviral medications, in consideration of infection prophylaxis.
In the efficacy evaluation, the ORR for the six patients was 33%. One patient each achieved CR and PR, three patients (50%) had SD and one patient (17%) had PD. The median time to response was 2.9 months. In the results from an overseas clinical study (10) conducted in 93 patients with relapsed or refractory B-CLL evaluating alemtuzumab at the same dosage for the same duration as in the present study, the ORR was 33% (two patients achieved CR and 29 patients had PR) and SD achieved in 54% of the patients. These results were similar to that in the present study and alemtuzumab is expected to be effective in the treatment of Japanese patients with relapsed or refractory B-CLL, although the efficacy data is preliminary due to small sample size of the present study.
On Week 12 after the last dosing of alemtuzumab 30 mg, C max , t max , AUC 0−τ and t 1/2 were significantly increased compared with these after the first dose, the maximum trough concentration came close to the steady-state level, and CL and V ss were reduced. At this time point, V ss was 8.64 L (equivalent to 0.17 L/kg for a body weight of 50 kg) and t 1/2 was 185.2 h (7.7 days). In an overseas clinical study (18) , AUC on Week 12 after the last dose of alemtuzumab at 30 mg by IV infusion every other day three times a week for 12 weeks was increased by approximately seven times that after the first dosing, and V ss and t 1/2 were 0.18 L/kg and 6 days, respectively. These PK parameters were generally consistent with the results from the present study. In this overseas clinical study conducted in B-CLL patients to whom alemtuzumab was administered by the same dosage regimen as in our study, the response rate (either CR or PR) reached 50% when the maximum trough concentration exceeded 13.2 μg/mL or when AUC 0-τ exceeded 484 μg × h/mL (18) . As AUC 0−τ in the last dose on Week 12 was 414-1651 μg × h/mL in our study, this dosage regimen is likely to be the enough level for efficacy in Japanese B-CLL patients.
These results, including PK data, seem to support the efficacy of alemtuzumab in Japanese relapsed or refractory B-CLL patients as well as the tolerability with the use of appropriate supportive therapy. The information regarding various side effects of alemtuzumab are included in the package insert (19). Particularly, serious infection diseases are reported in patients receiving alemtuzumab therapy. The prophylaxis treatment for the infectious diseases prior to the alemtuzumab administration, regular CMV tests and close monitoring to the patients are recommended, and the appropriate treatments are required if the infection diseases are observed in patients.
Conclusion
The safety profiles observed during the treatment with alemtuzumab in Japanese patients with relapsed or refractory B-CLL were similar to the results of overseas clinical studies. Also, the efficacy results as well as PK profile were generally consistent with the results from overseas studies. Therefore, the overseas dose of alemtuzumab at 30 mg by IV infusion every other day three times a week for 12 weeks should be safe and effective similarly in Japanese patients with relapsed or refractory B-CLL. Based on these results, Japanese Ministry of Health, Labour and Welfare approved alemtuzumab for the treatment of relapsed or refractory CLL in September 2014. 
